Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.
Adolescent
Adult
Anti-HIV Agents
/ pharmacology
Autoantibodies
/ blood
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
/ immunology
Female
HIV Infections
/ blood
HIV-1
/ immunology
Humans
Immunophenotyping
Lymphopenia
/ blood
Male
Middle Aged
Prospective Studies
Treatment Outcome
Viral Load
/ drug effects
AIDS/HIV
Autoimmune diseases
Genetic variation
T cells
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
18 04 2019
18 04 2019
Historique:
received:
03
01
2019
accepted:
12
03
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
20
6
2020
Statut:
epublish
Résumé
The goal of antiretroviral therapy (ART) is to suppress HIV-1 replication and reconstitute CD4+ T cells. Here, we report on HIV-infected individuals who had a paradoxical decline in CD4+ T cells despite ART-mediated suppression of plasma HIV-1 load (pVL). We defined such an immunological outcome as extreme immune decline (EXID). EXID's clinical and immunological characteristics were compared to immunological responders (IRs), immunological nonresponders (INRs), healthy controls (HCs), and idiopathic CD4+ lymphopenia (ICL) patients. T cell immunophenotyping and assembly/activation of inflammasomes were evaluated by flow cytometry. PBMC transcriptome analysis and genetic screening for pathogenic variants were performed. Levels of cytokines/chemokines were measured by electrochemiluminescence. Luciferase immunoprecipitation system and NK-mediated antibody-dependent cellular cytotoxicity (ADCC) assays were used to identify anti-lymphocyte autoantibodies. EXIDs were infected with non-B HIV-1 subtypes and after 192 weeks of consistent ART-mediated pVL suppression had a median CD4+ decrease of 157 cells/μl, compared with CD4+ increases of 193 cells/μl and 427 cells/μl in INR and IR, respectively. EXID had reduced naive CD4+ T cells, but similar proportions of cycling CD4+ T cells and HLA-DR+CD38+CD8+ T cells compared with IR and INR. Levels of inflammatory cytokines were also similar in EXID and INR, but the IL-7 axis was profoundly perturbed compared with HC, IR, INR, and ICL. Genes involved in T cell and monocyte/macrophage function, autophagy, and cell migration were differentially expressed in EXID. Two of the 5 EXIDs had autoantibodies causing ADCC, while 2 different EXIDs had an increased inflammasome/caspase-1 activation despite consistently ART-suppressed pVL. EXID is a distinct immunological outcome compared with previously described INR. Anti-CD4+ T cell autoantibodies and aberrant inflammasome/caspase-1 activation despite suppressed HIV-1 viremia are among the mechanisms responsible for EXID.
Sections du résumé
BACKGROUND
The goal of antiretroviral therapy (ART) is to suppress HIV-1 replication and reconstitute CD4+ T cells. Here, we report on HIV-infected individuals who had a paradoxical decline in CD4+ T cells despite ART-mediated suppression of plasma HIV-1 load (pVL). We defined such an immunological outcome as extreme immune decline (EXID).
METHODS
EXID's clinical and immunological characteristics were compared to immunological responders (IRs), immunological nonresponders (INRs), healthy controls (HCs), and idiopathic CD4+ lymphopenia (ICL) patients. T cell immunophenotyping and assembly/activation of inflammasomes were evaluated by flow cytometry. PBMC transcriptome analysis and genetic screening for pathogenic variants were performed. Levels of cytokines/chemokines were measured by electrochemiluminescence. Luciferase immunoprecipitation system and NK-mediated antibody-dependent cellular cytotoxicity (ADCC) assays were used to identify anti-lymphocyte autoantibodies.
RESULTS
EXIDs were infected with non-B HIV-1 subtypes and after 192 weeks of consistent ART-mediated pVL suppression had a median CD4+ decrease of 157 cells/μl, compared with CD4+ increases of 193 cells/μl and 427 cells/μl in INR and IR, respectively. EXID had reduced naive CD4+ T cells, but similar proportions of cycling CD4+ T cells and HLA-DR+CD38+CD8+ T cells compared with IR and INR. Levels of inflammatory cytokines were also similar in EXID and INR, but the IL-7 axis was profoundly perturbed compared with HC, IR, INR, and ICL. Genes involved in T cell and monocyte/macrophage function, autophagy, and cell migration were differentially expressed in EXID. Two of the 5 EXIDs had autoantibodies causing ADCC, while 2 different EXIDs had an increased inflammasome/caspase-1 activation despite consistently ART-suppressed pVL.
CONCLUSIONS
EXID is a distinct immunological outcome compared with previously described INR. Anti-CD4+ T cell autoantibodies and aberrant inflammasome/caspase-1 activation despite suppressed HIV-1 viremia are among the mechanisms responsible for EXID.
Identifiants
pubmed: 30996137
pii: 127113
doi: 10.1172/jci.insight.127113
pmc: PMC6538352
doi:
pii:
Substances chimiques
Anti-HIV Agents
0
Autoantibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Références
Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii18-ii24
pubmed: 15479865
Cell Host Microbe. 2015 Oct 14;18(4):463-70
pubmed: 26468749
Genome Biol. 2014;15(12):550
pubmed: 25516281
Clin Infect Dis. 2009 Feb 1;48(3):350-61
pubmed: 19123865
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
J Infect Dis. 2012 May 1;205(9):1382-90
pubmed: 22454463
Blood. 2014 Oct 9;124(15):2337-44
pubmed: 25163701
Transl Res. 2015 Feb;165(2):325-35
pubmed: 25241936
Arch Ophthalmol. 2003 Apr;121(4):491-9
pubmed: 12695246
Am J Ophthalmol. 2004 Dec;138(6):925-30
pubmed: 15629282
J Immunol. 1989 May 1;142(9):3091-7
pubmed: 2468713
J Infect Dis. 2013 Mar 15;207(6):880-92
pubmed: 23087435
AIDS Res Hum Retroviruses. 1987;3(4):409-22
pubmed: 2833917
J Infect Dis. 2011 Oct 15;204(8):1217-26
pubmed: 21917895
Front Immunol. 2014 Nov 03;5:531
pubmed: 25404929
PLoS One. 2013 Jul 03;8(7):e68431
pubmed: 23844200
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
J Clin Invest. 2018 Dec 3;128(12):5222-5234
pubmed: 30179220
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3408-16
pubmed: 23959892
Clin Infect Dis. 2009 Mar 15;48(6):787-94
pubmed: 19193107
Clin Infect Dis. 2016 Jan 15;62(2):258-261
pubmed: 26394669
J Infect Dis. 2014 Aug 15;210(4):619-29
pubmed: 24585897
Gut. 2006 Nov;55(11):1670-1
pubmed: 17047119
PLoS One. 2012;7(7):e39266
pubmed: 22815702
J Crohns Colitis. 2009 Dec;3(4):302-4
pubmed: 21172291
BMC Infect Dis. 2010 Nov 02;10:318
pubmed: 21044307
Nature. 2014 Jan 23;505(7484):509-14
pubmed: 24356306
Blood. 2008 Jul 15;112(2):287-94
pubmed: 18456875
Clin Med Insights Gastroenterol. 2018 Feb 20;11:1179552218757512
pubmed: 29497344
J Infect Dis. 2017 Jul 1;216(1):82-91
pubmed: 28498953
Nat Cell Biol. 2007 Oct;9(10):1102-9
pubmed: 17909521
Immunity. 2012 Mar 23;36(3):464-76
pubmed: 22361007
Arthritis Rheum. 2009 Jun;60(6):1862-6
pubmed: 19479871
Rheumatology (Oxford). 2000 Feb;39(2):142-7
pubmed: 10725063
PLoS Pathog. 2014 Dec 11;10(12):e1004543
pubmed: 25503054
AIDS. 2004 Feb 20;18(3):459-63
pubmed: 15090798
Genome Biol. 2006;7(10):R100
pubmed: 17076895